PharmAthene, Inc. [PIP] has completed its acquisition of the biodefense vaccines business unit from the United Kingdom's Avecia Biologics in a deal that bolsters its portfolio of anthrax vaccine capabilities and gives it a potential product for plague vaccine. Terms of the deal include a $10 million cash payment and additional $7 million to be paid within 18 months of the closing. Avecia will also be able to receive payments up to $23 million contingent upon the achievement of certain…
Recommended
Trending
Congress Updates
HASC Chair Rogers Casts Doubt On ‘Right To Repair’ Reform Making It Into Final FY ‘27 NDAA
The chair of the House Armed Services Committee has cast doubt on Congress including major “Right to Repair” reforms granting the military services’ greater ability to fix its own equipment […]
Navy Needs New Foreign-Backed U.S. Shipyard Focused on Frigates, Number Two Navy Civilian Nominee Says
The administration’s nominee to be the second highest civilian Navy official told senators Thursday the government should focus on having a foreign shipbuilder start a new U.S. shipyard focused on […]
Pentagon Needs Overarching Munitions Plan, GAO Says
In response to a charge from the fiscal 2025 National Defense Authorization Act to examine Pentagon munitions levels and offer recommendations, the Government Accountability Office (GAO) said in a new […]
Obadal Says Army To Deliver ‘Multi-Year Program Plans’ To Hill, As Appropriators Seek More Transparency
Senate appropriators have called on the Army to provide increased transparency into its major acquisition and modernization efforts, specifically seeking greater insight into the service’s future plans for its aviation […]